Successors Sweet Burden: 10.7 billion 26-year-old in charge of 100 billion companies

category:Finance
 Successors Sweet Burden: 10.7 billion 26-year-old in charge of 100 billion companies


Speaking of Xie Qirun, we are a little strange, but when it comes to Zhengda Group, nobody seems to know. After the reform and opening up, Zhengda Group, as the first foreign-funded enterprise invested in Shenzhen, has obtained the 001 foreign business license. At present, Xie Guomin, the head of Zhengda Group, is Xie Qiruns fourth uncle.

Nowadays, Zhengda Group is still in the situation of two or three generations, but the fourth generation of Zhengda cant wait to go to the front stage.

Beginning in Maolu, we have achieved a lot.

According to a research institute in the United States, about 70% of family businesses can not be passed on to the second generation, 88% can not be passed on to the third generation, and only 3% are still running family businesses after the fourth generation.

In 2019, listed companies disclosed successively that the performance of Chinas biopharmaceutical industry was remarkable. In the first half of the year, the revenue of Chinas biopharmaceutical industry was about 12.527 billion yuan, an increase of 28.8% over the previous year, and the net profit of Chinas listed companies was about 1.444 billion yuan, an increase of 5.8% over the previous year. And this listed company is managed by Zhengda No. 4 Metabolizing its profit.

In 2015, Xie Qirun graduated from Wharton Business School and entered a family business. He was only 23 years old and served as chairman and executive director of the board of directors of China Biopharmaceuticals. China Biopharmaceuticals is a listed company on the Hong Kong Stock Exchange. It has many subsidiaries. Xie Qirun took over with a market value of about 40 billion yuan. Many predecessors had doubts about Xie Qiruns ability to shoulder this responsibility, but as the companys performance has gone all the way, Xie Qirun has also been recognized.

When Asia Weekly selected the Hong Kong Stock Market List of Mainland Enterprises in 2015, China Biopharmaceuticals won the Private Enterprise Award of Maximum Market Value. China Biopharmaceuticals is one of the top five pharmaceutical companies listed in Forbes China. coms Top 50 Listed Companies in Asia in 2017. In 2018, Xie Qirun joined Dong Mingzhu and Tao Huabi in Forbeslist of outstanding women in Chinese business, ranking 25th.

Hundred Years Family, Brotherly Inheritance

Speaking of Xie Qirun, I have to mention her family story.

In 1953, at Xie Zhengmins suggestion, Xie Shaofei registered the Bubu Group, which was only called Zhengda Group in China. At the beginning of its establishment, Xie Zhengmin served as chairman. Five years later, Xie Zhengmin felt that his brother Xie Guomin had better management, so he gave up the chairmans seat to his brother. Since then, Xie Guomin took charge of Zhengda Group and became the real power holder. He also brought Zhengda into its heyday and developed into the richest family in Thailand.

After Xie Zhengmin resigned, he still devoted himself to supporting his brothers development behind the scenes. He still had prestige in Zhengda Group. He acted as a spokesperson for his brother outside and helped to receive guests at an advanced age, which is called brotherly affection.

Xie Ming has always attached great importance to domestic development. He was sent back to China by his father when he was a teenager. Since then, he has also been very concerned about the Chinese market. After the establishment of a Chinese joint venture in Shenzhen in 1979, Chinas business territory has become the most important sector of Xies family business.

Not long ago, 80-year-old Xie Guomin also published three huge advertisements in Ming Pao, Xingdao Daily and Oriental Daily in Hong Kong, expressing his views on the situation in Hong Kong in 16 words: Stop riots, restore order, maintain the rule of law and promote prosperity altogether.

Three generations of baton and four generations of baton

In 2017, Xie Guomin resigned from the post of group chairman and assumed the post of senior chairman. The third generation officially took over.

Where wealth gathers, where struggle hides. Compared with many rich families in Asia, the old and new generations are inevitably bleeding. Xies three dynasties are now changing, with undercurrent surging behind his back. His brothers and brothers are respectful in the face, and one generation is better than the other. Thanks to Xies decision in the 1980s to break down the family hereditary system, the next generation of children entering the family business must be outstanding performers if they are to be approved by the board of directors. That is to say, Xie Jiaxuans choice of the person in power is not obsessed with the eldest son of the long house, but the person who can live in it.

Therefore, although Xie Zhengmin gave way to his brother Xie Guomin, it does not mean that Xie Zhengmin quit the core management of Zhengda Group.

Xie Zhengmins son, Xie Bing, Xie Qiruns father, is the executive vice president of Zhengda Group. Under his uncles deployment, he leaped to the health industry in the 1990s. Now he runs Zhengda Pharmaceutical Group, and has participated in and controlled dozens of domestic pharmaceutical enterprises successively, which makes the business territory of Xie family in China expand continuously. Zheng Xiangling, Xie Qiruns mother, was born in rural Shaanxi Province. After marrying Xie Bing, she set up Beijing Tede Company in a small workshop, which is now a giant company producing targeted drugs. Established with her husband, China Biopharmaceuticals is now under the control of her daughter Xie Qirun, but Zheng Xiangling is still the companys actual controller, ranking 10th on Huruns list of women entrepreneurs with a value of 27 billion yuan in 2018. With a prominent life experience, parentsability is obvious to all, the future Xie Qirun can go to where, let people wait and see. Source: Yang Bin_NF4368, Responsible Editor of China Times

Xie Zhengmins son, Xie Bing, Xie Qiruns father, is the executive vice president of Zhengda Group. Under his uncles deployment, he leaped to the health industry in the 1990s. Now he runs Zhengda Pharmaceutical Group, and has participated in and controlled dozens of domestic pharmaceutical enterprises successively, which makes the business territory of Xie family in China expand continuously.

Zheng Xiangling, Xie Qiruns mother, was born in rural Shaanxi Province. After marrying Xie Bing, she set up Beijing Tede Company in a small workshop, which is now a giant company producing targeted drugs. Established with her husband, China Biopharmaceuticals is now under the control of her daughter Xie Qirun, but Zheng Xiangling is still the companys actual controller, ranking 10th on Huruns list of women entrepreneurs with a value of 27 billion yuan in 2018.

With a prominent life experience, parentsability is obvious to all, the future Xie Qirun can go to where, let people wait and see.